

CURRICULUM VITAE

Name: Neal Paul Christiansen, M.D.

Address:

Office: Hematology/Oncology Division (843) 792-4271
Medical University of South Carolina
96 Jonathan Lucas Street - 903 CSB
P.O. Box 250635
Charleston, SC 29425

EDUCATION:

Valparaiso University
Valparaiso, IN
1973 – 1977 (May 22)
Bachelor of Science – Biology and Chemistry

Washington University School of Medicine
St. Louis, MO
1977 – 1981 (May 22)
M.D.

Michael Reese Hospital and Medical Center
Chicago, IL
1981 – 1982
Internship – Internal Medicine

Michael Reese Hospital and Medical Center
Chicago, IL
1982 – 1984
Residency – Internal Medicine

University of Minnesota Hospital and Clinic
Minneapolis, MN
1984 – 1986
Fellowships – Division of Medical Oncology

EXAMINATIONS:

1982 Diplomate, National Board of Medical Examiners
1984 Diplomate, American Board of Internal Medicine
1987 Diplomate, Medical Oncology

FACULTY APPOINTMENTS:

Assistant Professor of Medicine
Medical University of South Carolina
Division of Hematology/Oncology
Charleston, SC
04/2009 – Present

South Carolina Oncology Associates, P.A.
Columbia, SC
03/1999 – 03/2009

Clinical Director, Associate Professor of Medicine
University of South Carolina School of Medicine
Division of Transplantation Medicine – Richland Memorial Hospital
Columbia, SC
08/1996 – 03/1999

Assistant Professor of Medicine
Divisions of Hematologic Oncology and Bone Marrow Transplantation
Roswell Park Cancer Institute
Buffalo, NY
10/1990 – 08/1996

Assistant Professor of Medicine
Division of Hematology/Oncology
University of Tennessee College of Medicine
Memphis, TN
06/1988 – 10/1990

Instructor of Medicine
Division of Medical Oncology
University of Minnesota School of Medicine
Minneapolis, MN
07/1986 – 06/1988

HOSPITAL APPOINTMENTS:

Palmetto Baptist medical Center,
Lexington Memorial Hospital
Columbia, SC
Consultant/Courtesy: 1999 – 2009

Kershaw County Medical Center

Camden, SC
Consultant/Courtesy: 1999 – 2009

The Regional Medical Center
Orangeburg, SC
Consultant/Courtesy: 1999 – 2009

Providence Hospitals
Columbia, SC
Consultant/Courtesy: 1999 – 2009

Palmetto Richland Memorial Hospital
Columbia, SC
Active: 1996 – 2009

Buffalo General Hospital
Buffalo, NY
Courtesy Staff: 1995 – 1996

Roswell Park Cancer Institute
Buffalo, NY
Active: 1990 – 1996

Veteran's Administration Medical Center,
William F. Bowld Hospital,
The Regional Medical Center
Memphis, TN
Active: 1988 – 1990

Baptist Memorial Hospital
Memphis, TN
Consultant: 1988 – 1990

University of Minnesota Hospital
Minneapolis, MN
Active: 1986 – 1988

St. Luke's Hospital
Aberdeen, SD
Consultant: 1986 – 1988

HOSPITAL COMMITTEES/ACTIVITIES:

Chief, Medical Staff

Palmetto Richland Memorial Hospital
2007 – 2009

Chair, Department of Oncology Services
Palmetto Richland Memorial Hospital
2006 – 2009

Vice Chief, Medical Staff
Palmetto Richland Memorial Hospital
2006 – 2009

Secretary, Medical Staff
Palmetto Richland Memorial Hospital
2005 – 2009

Director of Research
SCOA Practice Responsibilities
2005 – 2009

Director of Education
SCOA Practice Responsibilities
2004 – 2009

Research Advisory Committee
South Carolina Cancer Center
2001 – 2005

Chair, Oncology Committee
Palmetto Richland Memorial Hospital
2001 – 2004

Medical Executive Committee,
Chair, Department of Oncology Services
Palmetto Richland Memorial Hospital
2000 – 2003

Vice Chair, Department of Oncology Services
Palmetto Richland Memorial Hospital
2000 – 2001

Ethics Committee
Palmetto Richland Memorial Hospital
1997 – 2009

Executive Committee,
Clinical Trials Barriers Committee,
Clinical Trials Committee

South Carolina Cancer Center
1997 - 2000

BMT Patient Care Committee,
Division of Transplantation Medicine,
Medical Director, Stem Cell Processing Laboratory,
Medical Director, Therapeutic Apheresis
Palmetto Richland Memorial Hospital
1997 – 1999

Nominating Committee,
By-Laws Committee
Roswell Park Cancer Institute
1996 – 1996

Critical Care Utilization Review Subcommittee,
Executive Committee,
Nutritional Advisory Committee
Roswell Park Cancer Institute
1994 – 1996

Ethics Committee, Operating Room Committee
Roswell Park Cancer Institute
1993 – 1996

Critical Care Committee,
Alternate, Institutional Review Board
Roswell Park Cancer Institute
1993 – 1996

Blood Products Committee,
Director, Stem Cell Processing Laboratory,
Director/Assoc. Director, Therapeutic Apheresis
Roswell Park Cancer Institute
1991 – 1996

Advisor, Chemotherapy Clinic
Roswell Park Cancer Institute
1991 – 1991

Scientific Review Committee, Infection Control Committee
Roswell Park Cancer Institute
1990 – 1996

Phase I-II Subcommittee, Stem Cell Advisory Board

Roswell Park Cancer Institute
1990 – 1991

Human Studies Subcommittee, Transfusion Committee
VA Medical Center
Memphis, TN
1989 – 1990

Director, Stem Cell Processing Laboratory
University of Tennessee
Memphis, TN
1989 – 1990

Home Health Committee
University of Minnesota Hospital
1986 – 1988

LICENSURE:

1996 South Carolina

PROFESSIONAL SOCIETIES:

1998 – 2009 Member, Columbia Medical Society
1995 Fellow, American College of Physicians
1993 – 2000 Member, American Society for Blood and Marrow Transplantation
1993 – 2000 Member, International Society for Hematotherapy and Graft Engineering
1989 Member, American Society of Hematology
1988 Member, American Association for Cancer Research
1986 Member, American Society of Clinical Oncology
1986 Member, American College of Physicians

PUBLICATIONS (original articles):

Original Articles :

1. Roemeling RV, **Christiansen NP**, Hrushesky WJ. Lack of anti-emetic effect of high dose metoclopramide. J Clin Oncol 1985; 3:1273-6.
2. Shapiro C, **Christiansen N**, Fretzin D, Evans R, Ross D. Muir-Torre Syndrome. J Surg Oncol 1986; 31:160-2.

3. Shapiro CM, Beckmann E, **Christiansen N**, Bitran JD, Kozloff M, Billings AA, Teler MC. Immunologic status of patients in remission from Hodgkin's disease and disseminated malignancies. *Am J Med Science* 1987; 293:365-70.
4. **Christiansen NP**, Skubitz KM. Identification of the major lectin-binding proteins of human neutrophils and alveolar macrophages. *Blood* 1988; 71:1624-32.
5. **Christiansen NP**, Skubitz KM, Nath K, Ochoa A, Kennedy BJ. Nephrotoxicity of continuous intravenous infusion of recombinant interleukin-2. *Am J med* 1988; 84:1072-5.
6. **Christiansen NP**, Kennedy BJ. Combination chemotherapy with etoposide and 5-fluorouracil in advanced pancreatic adenocarcinoma. *Am J Clin Oncol* 1989; 12:46-8.
7. Skubitz KM, **Christiansen NP**, Mendiola Jr. Preparation and characterization of monoclonal antibodies to human cathepsin G, lactoferrin, eosinophil peroxidase, and eosinophil major basic protein. *J Leukoc Biol* 1989; 46:109-18.
8. **Christiansen NP**, Kennedy BJ, Skubitz KM, Ochoa AC, Bach FH. Continuous infusion recombinant interleukin-2 and lymphokine-activated killer cells in refractory malignancies. *Med Pediatr Oncol* 1989; 17:455-8.
9. Hurd DD, Lasky LC, Haake RJ, **Christiansen NP**, McGlave PB, Bostrom BC, Levine EG, Weisdorf DJ, Kim TH, Peterson BA, Bloomfield CD. Treatment of refractory and relapsed Hodgkin's disease: intensive chemotherapy and autologous bone marrow or peripheral blood stem cell support. *Med Pediatr Oncol* 1990; 18:447-53.
10. Harvath L, Balke JA, **Christiansen NP**, Russell AA, Skubitz KM. Selected antibodies to leukocyte common antigen (CD45) inhibit human neutrophil chemotaxis. *J Immunol* 1991; 146:949-57.
11. **Christiansen NP**, Haake RJ, Hurd DD. Early herpes zoster infections in adult patients with Hodgkin's disease undergoing autologous bone marrow transplantation. *Bone Marrow Transplant* 1991; 7:435-7.
12. Baer MR, Frankel SR, **Christiansen NP**, Caligiuri MA, Bernstein SH, Mrózek K, Bloomfield CD, Herzig GP. High-dose cytosine arabinoside, idarubicin and G-CSF therapy for *de novo* and secondary adult acute myeloid leukemia. *Leukemia and Lymphoma* 1992; 7(suppl 2):8-10.
13. Baer MR, **Christiansen NP**, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig, GP. High dose cytarabine, idarubicin and granulocyte colony-stimulating factor remission induction therapy for previously untreated *de novo* and secondary adult acute myeloid leukemia. *Semin Oncol* 1993; 20 (suppl 8):6-12.
14. D'Atri S, Piccioni D, Castellano A, Tuorto V, Franchi A, Lu K, **Christiansen N**, Frankel S, Rustum YM, Papa G, Mandelli F, Bonmassar E. Chemosensitivity to triazene compounds

and O⁶-alkylguanine-DNA alkyltransferase levels: studies with blasts of leukaemic patients. *Ann Oncol* 1995; 6:389-93.

15. Baer MR, Bernstein SH, Brunetto VL, Heinonen K, Mrózek K, Swann VL, Minderman H, Block AW, Pixley LA, **Christiansen NP**, Fay JW, Barcos M, Rustum Y, Herzig GP, Bloomfield CD. Biologic effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia. *Blood* 1996; 87:1484-94.
16. Bernstein SH, **Christiansen NP**, Fay JW, Brown R, Herzig R, Frankel S, Blumenson L, Herzig GP. Granulocyte-macrophage colony stimulating factor (GM-CSF) priming of high dose etoposide and cyclophosphamide: a pilot trial. *Exp Hematol* 1996; 24:1363-68.
17. Herzig RH, Lynch J, **Christiansen, NP**, Fay JW, Davis MP, Herzig GP. Dose-intensive chemotherapy with etoposide-cyclophosphamide for advanced breast cancer. North American Transplant Group. *Semin Oncol* 1996; 23 (suppl 4):28-32.
18. Laughlin MJ, **Christiansen NP**, Herzig, GP, Blumenson L, Bonney D, Stewart CC. CD34 progenitor cell subset analyses in normal human bone marrow and marrow harvested after intermediate-dose chemotherapy. *Cytometry* 1996; 26:235-42.
19. Jurlander J, Caligiuri MA, Ruutu T, Baer MR, Strout MP, Oberkircher AR, Hoffman L, Ball ED, Frei-Lahr DA, **Christiansen NP**, Block AMW, Knuutila S, Herzig GP, Bloomfield CD. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. *Blood* 1996; 88:2183-91.
20. Bernstein SH, Eaves CJ, Herzig R, Fay J, Lynch J, Phillips GL, **Christiansen NP**, Reece D, Ericson S, Stephan M, Kovalsky M, Hawkins K, Rasmussen H, Devos A, Herzig GP. A randomized phase II study of BB-10010; a variant of human macrophage inflammatory protein-1 α for patients receiving high dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer. *Br J Hematol* 1997; 99:888-95.
21. Bernstein SH, Fay J, **Christiansen NP**, Pineiro L, Shah D, Stephan M, Herzig G. sequential interleukin-3 (IL-3) and granulocyte-colony stimulating factor (G-CSF) prior to and following high dose etoposide and cyclophosphamide: a Phase I/II trial. *Clin Cancer res* 1997; 3:1519-26.
22. Ratanatharathorn V, Nash RA, Przepioroka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, **Christiansen NP**, van der Jagt R, Herzig RH, Litzow, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR. Phase III study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. *Blood* 1998; 92:2303-14.
23. Bernstein SH, Fay J, Frankel S, **Christiansen N**, Baer MR, Jacobs C, Blosch C, Hanna R, Herzig G. A phase I study of recombinant human soluble interleukin-1 receptor (rhu IL-1R) in patients with relapsed and refractory acute myeloid leukemia. *Cancer Chemother Pharmacol* 1999; 43:141-44.

24. Schriber J, Milk B, Shaw D, **Christiansen N**, Baer M, Slack J, Tezcan H, Wetzler M, Herzig G. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation. *Bone Marrow Transplant* 1999; 24:1311-4.
25. Godder KT, Hazlett LJ, Abhyankar SH, Chiang KY, **Christiansen NP**, Bridges KD, Lee CG, Geier SS, Goon-Johnson KS, Gee AP, Pati AR, Parrish RS, Henslee-Downey PJ. Partially mismatched related-donor bone marrow transplantation for pediatric patients with acute leukemia: younger donors and absence of peripheral blasts improve outcome. *J Clin Oncol* 2000; 18:1856-66.
26. DeRienzo SY, Chiang KY, O'Neal WM, Godder K, Abhyankar S, **Christiansen NP**, Bridges KD, Henslee-Downey PJ. Evaluation of the half-life of intravenous human cytomegalovirus immune globulin in patients receiving partially mismatched related donor bone marrow transplantation. *Pharmacotherapy* 2000; 20:1175-78.
27. Chiang KY, Hazlett LJ, Godder KT, Abhyankar SH, **Christiansen NP**, van Rhee F, Lee CG, Bridges K, Parrish RS, Henslee-Downey PJ. Epstein-Barr virus-associated B cell lymphoproliferative disorder following mismatched related T cell-depleted bone marrow transplantation. *Bone Marrow Transplant* 2001; 28:1117-23.
28. Linker C, Anderlini P, Herzig R, **Christiansen N**, Somlo G, Bensinger W, Fay J, Lynch JP, Goodnough LT, Ashby M, Benyunes MC, Jones DV, Yang TA, Miller LL, Weaver C. Recombinant human thrombopoietin augments mobilization of peripheral blood progenitor cells for autologous transplantation. *Biol Blood Marrow Transplant* 2003; 9:405-13.
29. Vose JM, Rizzo DJ, Tao-Wu J, Armitage JO, Bashey A, Burns LJ, **Christiansen NP**, Freytes CO, Gale RP, Gibson J, Giralt SA, Herzig RH, Lemaistre CF, McCarthy PL Jr, Nimer SD, Petersen FB, Schenkein DP, Wiernik PH, Wiley JM, Loberiza FR, Lazarus HM, van Biesen K, Horowitz MM. Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission. *Biol Blood Marrow Transplant*. 2004 Feb; 10:116-27.
30. Tallman MS, Perez WS, Lazarus HM, Gale RP, Maziarz RT, Rowe Jm, Marks DI, Cahn JY, Bashey A, Bishop MR, **Christiansen N**, Frankel SR, Garcia JJ, Ilhan O, Laughlin MJ, Liesveld J, Linker C, Litzow MR, Luger S, McCarthy PL, Milone GA, Pavlovsky S, Phillips GL, Russell JA, Saez RA, Schiller G, Sierra J, Weiner RS, Zander AR, Zhang MJ, Keating A, Weisdorf D, Horowitz MM. Pretransplantation consolidation chemotherapy decreases leukemia relapse after autologous blood and bone marrow transplants for acute myelogenous leukemia in first remission. *Biol Blood Marrow Transplant* 2005; 12:204-16.
31. Treat J, Bonomi P, McCleod M, **Christiansen NP**, Mintzer DM, Monberg MJ, Ye Z, Chen R, Obasaju CK. Administration of pemetrexed immediately following gemcitabine as front-line therapy in advanced non-small cell lung cancer: a phase II trial. *Lung* 2006; 53:77-83.

CHAPTERS/REVIEWS:

1. **Christiansen NP**. ?Allogeneic bone marrow transplantation for the treatment of adult acute leukemias. *Hematol Oncol Clin North Am* 1993; 7:177-200.
2. Herzig RH, Lynch J, **Christiansen NP**, Fay JW, Davis MP, Stevens DA, Pineiro L, Herzig GP. Dose-intensive chemotherapy with etoposide-cyclophosphamide without stem cell support for advanced breast cancer: preliminary results. In: Dicke Ka, Keatin A, editors. Autologous marrow and blood transplantation. Proceedings of the Seventh International Symposium; 1994 August 17-20; Arlington (TX). Arlington (TX): The Cancer Treatment Research and Educational Institute, 1995, 211-14.
3. **Christiansen N**. Pancreatic carcinoma. *J South Carolina Med Assoc* 2003; 99:79-81.

ABSTRACTS:

1. **Christiansen N**, Shapiro C, Beckman E. Immunologic status in cured Hodgkin's patients. *Clin Res* 1984; 32:751A.
2. **Christiansen N**, Kennedy BJ. Treatment of advanced adenocarcinoma of the pancreas with etoposide and 5-fluorouracil. *Proc Amer Soc Clin Oncol* 1986; 5:93.
3. **Christiansen N**, Kennedy BJ, Ochoa A, Skubitz K, Bach FH. Toxicities of repeated courses of short- and long-term lymphokine activated killer cells and interleukin-2. *Proc Amer Soc Clin Oncol* 1987; 6:242.
4. ***Christiansen NP**, Skubitz KM. Identification of the major lectin binding surface proteins of human neutrophils and alveolar macrophages. *Clin Res* 1987; 35:890A.
5. ***Christiansen NP**, Skubitz KM. Characterization of the major lectin-binding surface proteins of human neutrophils and alveolar macrophages. *Blood* 1987; 70 Suppl 1:86A.
6. ***Christiansen NP**, Skubitz KM, Nath K, Ochoa A, Kennedy BJ. Inhibition of renal prostaglandin synthesis by recombinant interleukin-2. *Proc Amer Assoc Cancer Res* 1988; 29:397.
7. Hurd D, Lasky L, Haake R, Peterson B, Kim T, **Christiansen N**, Weisdorf D, Bostrom B, Levine E, McGlave P, Bloomfield C. Autologous transplantation in Hodgkin's disease using bone marrow or peripheral blood derived stem cells. *Proc Amer Soc Clin Oncol* 1988; 7:177.
8. ***Christiansen NP**, Hurd DD. Risk factors for herpes zoster infection in patients with Hodgkin's disease undergoing autologous bone marrow transplantation. *Blood* 1988; 72 Suppl 1:383A.

9. Niell HB, Griffin JP, Turman E, Taylor G, **Christiansen N**, French M. Cisplatin, mitomycin-C, vinblastine and methotrexate in the treatment of patients with stage III and IV non-small cell lung cancer. Proc Amer Soc Clin Oncol 1989; 8:229.
10. ***Christiansen NP**, Hurd DD. Herpes zoster infection following autologous bone marrow transplantation for Hodgkin's disease. J Cellular Biochem 1990; Suppl 14A:310.
11. Niell HB, Griffin JP, Lands R, Miller A, **Christiansen N**, Paig CU, Memula N, French M. Neoadjuvant chemotherapy plus radiation therapy for limited non-small cell lung cancer. Proc Amer Soc Clin Oncol 1990; 9.
12. Laughlin M, **Christiansen NP**, Stewart CC, Nettleton A, Bonney D, Herzig GP. Measurement of lineage-committed CD-34+ bone marrow progenitors in allogeneic transplantation. Blood 1993; 82 Suppl 1:650a.
13. Laughlin M, **Christiansen NP**, Stewart CC, Bonney D, Herzig GP. Analyses and significance of CD34+ cells in peripheral blood (PBSC) and bone marrow (BM) in autologous bone marrow transplantation (AuBMT) for breast cancer. Proc Amer Soc Clin Oncol 1994; 13:110.
14. *Strout MP, Oberkircher AR, Herzig GP, Fritz NP, Baer MR, Frankel SR, **Christiansen NP**, Caligiuri MA. Molecular evaluation of engraftment following non-T cell depleted allogeneic bone marrow transplantation (BMT): evidence for mixed chimerism in specific leukocyte subpopulations. Proc Amer Soc Clin Oncol 1994; 13:306.
15. Bernstein SH, **Christiansen NP**, Frankel S, Baer MR, Czuczman M, Brown R, Fay J, Herzig GP. Priming with GM-CSF prior to high dose etoposide and cyclophosphamide. Proc Amer Soc Clin Oncol 1994; 13:452.
16. *Collins R, Wolff S, List A, **Christiansen N**, Pineiro L, Greer J, Goodman S, Dalton W, Gonzalez G, Herzig G, Phillips G, Fay J. Prospective multicenter trial of donor buffy coat infusion for relapsed hematologic malignancy post-allogeneic bone marrow transplantation (BMT). Blood 1994;84 (suppl 1):333a.
17. Herzig R, Lynch J, **Christiansen N**, Fay J, Davis M, Stevens D, Collins R, Bernstein S, Pineiro L, Herzig G. Dose-intensive chemotherapy with etoposide-cyclophosphamide (VP-CY) without stem cell support for advanced breast cancer: a study of the North American Marrow Transplant Group. Proc Amer Soc Clin Oncol 1995; 14:323.
18. *Fay J, Jones S, Lynch J, herzig R, **Christiansen N**, Pineiro L, Collins R, Freeman B, Herzig G. The treatment of primary breast cancer with intensive thiotepa (TPA), cyclophosphamide (CPA), and hematopoietic stem cell (HSC) transplantation – a Phase II trial of the North American Marrow Transplant Group. Proc amer Soc Clin Oncol 1995;14:104.

19. *Schriber J, **Christiansen N**, Baer MR, Slack J, Wetzler M, Herzig G. Tissue plasminogen activator (tPA) as therapy for hepatotoxicity following bone marrow transplantation (BMT). Blood 1995; 86 (suppl 1):220a.
20. *Jurlander J, Caligiuri MA, Strout MP, Ball ED, Frei-Lahr DA, Hoffman L, Oberkircher AR, **Christiansen NP**, Block AW, Herzig GP, Bloomfield CD. Persistence of the t(8;21) fusion transcript following allogeneic (allo) bone marrow transplantation (BMT) for acute myeloid leukemia (AML). Blood 1995; 86 (suppl 1):569a.
21. Bernstein SH, Fay JW, **Christiansen N**, Pineiro L, Herzig R, Herzing G. Sequential interleukin-3 (IL-3) & granulocyte-colony stimulating factor (G-CSF) priming of high dose etoposide (VP) and cyclophosphamide (CY). Blood 1995; 86 (suppl 1):687a.
22. **Christiansen NP**, Pineiro L, Collins R, Fay J, Herzig G. thiotepa/carboplatin for allogeneic bone marrow transplantation (BMT). Blood 1995; 86 (suppl 1):941a.
23. Schriber J, **Christiansen N**, Baer MR, Slack J, Wetzler M, Herzig G. High dose thiotepa and carboplatinum preparative regimen for autologous bone marrow transplantation (BMT): a Phase I-II study. Blood 1995; 86 (suppl 1):964a.
24. *Loewen GM, **Christiansen, N**, Travaglia P, Westney G, Herzig G. Peak exercise oxygen uptake is predictive of bone marrow transplant mortality. Chest 1996; 110 (suppl):64s.
25. *Ratanatharathorn V, Nash R, Devine S, Przepioraka D, Klein J, Weisdorf D, Fay J, Nadamane A, Antin J, **Christiansen N**, van der Jagt R, Herzig R, Litzow M, Wolff S, Longo W, Petersen F, Buell D, Maher R, Fitzsimmons W, Wingard J. Phase III study comparing tacrolimus (Prograf, FK506) with cyclosporine for graft versus host disease (GVHD) prophylaxis after HLA-identical sibling bone marrow transplantation (BMT). Blood 1996; 88 (suppl 1):459a.
26. *Schriber JR, Mookerjee BK, Baer MR, **Christiansen NP**, McCarthy PL, Slack JL, Tezcan H, Wetzler M, Herzig GP. Efficacy of hemodialysis (HD) after allogeneic bone marrow transplantation. Blood 1996; 88 (suppl 1):118a.
27. *Schriber JR, Milk BJ, Baer MR, **Christiansen NP**, McCarthy PL, Slack JL, Tezcan H, Wetzler M, Herzig GP. A randomized phase II trial comparing heparin (Hep) ± prostaglandin E1 (PG) to prevent hepatotoxicity (HT) following bone marrow transplantation (BMT): preliminary results. Blood 1996; 88 (suppl 1):413a.
28. Schriber JR, Baer MR, **Christiansen NP**, McCarthy PL, Slack JL, Tezcan H, Wetzler M, Herzig GP. Murine monoclonal antibody directed against CD3 (OKT3) is an effective treatment for moderate (grade II) but not for severe (grade III or IV) steroid resistant graft versus host disease (GVHD). Blood 1996; 88 (suppl 1):265b.
29. *Alam A, Baer M, Bernstein S, Bernstein Z, **Christiansen NP**, Czuczman M, Schriber J, Slack J, Tezcan H, Wetzler M, Cooper M, Milk B, Ford L, Herzig G, McCarthy P. Phase II clinical trial of OKT3 for acute graft-versus-host disease (GVHD) prophylaxis in allogeneic

- bone marrow transplantation (alloBMT). *Blood* 1997; 90 (suppl 1):102a.
30. *Abhyankar S, **Christiansen N**, Godder K, Chiang KY, McGuirk J, Lee C, Gee A, Parrish R, Hazlett L, Bridges K, Henslee-Downey PJ. Partially mismatched related donor bone marrow transplant (PMRD BMT) for chronic myeloid leukemia (CML) in first chronic phase. *Blood* 1997; 90 (suppl 1):107a.
31. *Alidina A, Baer M, Bernstein S, Bernstein Z, **Christiansen NP**, Czuczman M, Schriber J, Slack J, Spangenthal T, Tezcan H, Wetzler M, Milk B, Swinnich D, Ford L, Herzig G, McCarthy P. Thiotepa-associated cardiomyopathy during hematopoietic stem cell transplantation. *Blood* 1997; 90 (suppl 1):223a.
32. Bernstein SH, Eaves CJ, Herzig R, Fay J, Lynch J, Phillips GL, **Christiansen NP**, Reece D, Ericson S, Stephan M, Kovalsky M, Hawkins K, Rasmussen H, de Vos A, Herzig GP. A randomized phase II study of BB-10010; a variant of human macrophage inflammatory protein-1 α (MIP-1 α) for patients receiving high dose etoposide and cyclophosphamide for malignant lymphoma and breast cancer. *Blood* 1997; 90 (suppl 1):182b.
33. *Strange P, McGuirk JP, **Christiansen NP**, Godder K, Abhyankar S, Chiang KY, Hazlett L, Parrish R, Henslee-Downey PJ. Cardiac and pulmonary changes following partially mismatched related donor bone marrow transplant and correlations to functionality of patients. *Clin Res* 1998;
34. *Abhyankar S, Godder K, Chiang KY, **Christiansen NP**, Brown J, DeRienzo S, O'Neal W, Henslee-Downey PJ. Extracorporeal photopheresis (ECP) with UVADEX™ for the treatment of chronic graft versus host disease (CGVHD). *Experimental Hematology* 1998;26:361.
35. *Baer MR, Pixley LA, Lawrence D, O'Loughlin KL, Adel-Razeq S, Block AW, Sait SNJ, Wetzler M, **Christiansen NP**, Frankel SR, Herzig GP, Bloomfield CD. High-dose cytarabine and idarubicin (HDAC/IDA) is effective remission induction therapy for older *de novo* but not for secondary acute myeloid leukemia (AML) patients. *Blood* 1998; 92(suppl 1):231a.
36. ***Christiansen NP**, Bridges K, Hazlett L, Abhyankar S, Chiang KY, Godder K, Lee C, Neglia W, Parrish R, Henslee-Downey PJ. Partially mismatched related donor (PMRD) is highly effective for patients with early leukemia. *Proc Amer Soc Clin Oncol* 1999; 18:55a.
37. *Godder K, Adams S, Chiang KY, vanRhee F, Metha J, Bridges K, DiRienzo S, O'Neal W, **Christiansen NP**, Henslee-Downey PJ. GM-CSF enhances the anti-leukemic effect of partially mismatched related donor stem cell transplant. *Proc Amer Soc Clin Oncol* 2000; 19:48a.
38. Treat J, . Pemetrexed plus gemcitabine as front-line therapy for patients with advanced stage non-small cell lung cancer. *Proc Amer Soc Clin Oncol* 2004;

39. Kozloff M, . Safety of bevacizumab (BV, Avastin) among patients (pts) receiving first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC) – preliminary results from a large registry in the US. Proc Amer Soc Clin Oncol 2005;
40. *Alban A, Chanan-Khan, Niesvizky R, Hohl RJ, Zimmerman TM, **Christiansen NP**, Schiller GJ, Smith S, Frankel S. Randomized multicenter phase 3 trial of high-dose dexamethasone (dex) with or without oblimersen sodium (G3139: bcl-2 antisense; Genasense) for patients with advanced multiple myeloma (MM). Blood 2004;104:413a.
41. McCleod M, . Pemetrexed (p) plus gemcitabine (g) as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC): a phase II clinical trial. Proc Amer Soc Clin Oncol 2005;
42. Kozloff M, . Safety of bevacizumab (BV) among patients (pts) receiving first-line chemotherapy for metastatic colorectal cancer: updated results from a large observational study in the U.S. (BRITE). Gastrointestinal Cancers Symposium, 2006; abstract 247.
43. Mena RR, **Christiansen NP**, Markan Y, Pandit L. A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, Cytosan and Rituxan (PCR) in the treatment of previously untreated or treated, stage III or IV, low-grade B-cell NHL. Proc Amer Soc Clin Oncol 2006;
44. Mena RR, **Christiansen NP**, Markan Y, Pandit L. A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, Cytosan and Rituxan (PCR) in the treatment of previously untreated or treated, bulky stage II, stage III or IV, low-grade B-cell NHL. Blood 2006; 108:4709.
45. *Christiansen NP, . A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, Cytosan and Rituxan (PCR) in the treatment of previously untreated or treated, stage III or IV, low-grade B-cell non-Hodgkin's Lymphoma (NHL) or bulky stage II lymphoma. Proc Amer Soc Clin Oncol 2007;
46. Mena RR, **Christiansen NP**, Markan Y, Pandit L. A multi-center, open-label study to evaluate the safety and efficacy of pentostatin, Cytosan and Rituxan (PCR) in the treatment of previously untreated or treated, stage III or IV, low-grade B-cell non-Hodgkin's Lymphoma (NHL) or bulky stage II lymphoma. Blood 2007; 110:1354.

* = Accepted for poster or platform presentation